Innovation | Novartis

Press Release
Apr 03, 2025

test media release format
Press Release
Apr 03, 2025

test media release format
Story
Oct 29, 2024

My journey to Novartis: Finding my purpose and passion
Story
Aug 02, 2024

Is Diversity, Equity and Inclusion (DEI) really that important?
Story
Apr 29, 2024

From black holes to AI driven drug discovery – collaboration wins the day
Press Release
Apr 23, 2024

Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Press Release
Apr 23, 2024

Novartis, au premier trimestre: croissance à deux chiffres du chiffre d’affaires et expansion de la marge core; hausse des prévisions pour 2024
Press Release
Apr 23, 2024

Novartis erzielt im ersten Quartal ein zweistelliges Umsatzwachstum und steigert die Kerngewinnmarge; Prognose für das Geschäftsjahr 2024 erhöht
Press Release
Apr 17, 2024

Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Press Release
Apr 15, 2024

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Press Release
Mar 04, 2024

Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
Press Release
Jan 31, 2024

Novartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III